Erturk Kayhan, Tas Faruk, Serilmez Murat, Bilgin Elif, Duranyildiz Derya
Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul 34093, Turkey.
Mol Clin Oncol. 2018 Jan;8(1):204-208. doi: 10.3892/mco.2017.1493. Epub 2017 Nov 8.
Neural precursor cell-expressed developmentally downregulated protein 9 (NEDD9) is a promoter for various cellular functions that result in tumorigenesis. The aim of the present study was to analyse the serum levels of NEDD9 in melanoma patients in order to evaluate its prognostic, predictive and diagnostic value. Data from 112 melanoma patients were retrospectively analyzed and ELISA assays were used to measure serum NEDD9 concentration. The median serum NEDD9 levels of the patients were significantly higher compared with those of the controls. Serum NEDD9 was not found to be associated with any of the clinicopathological parameters, and was also not found to be prognostic for survival in melanoma. Therefore, serum NEDD9 may be of diagnostic value in melanoma, but its usefulness in prognosis remains controversial. The important role of NEDD9 in tumor angiogenesis necessitates efforts to elucidate its interactions with the tumor microenvironment and its potential as a therapeutic target for malignancies.
神经前体细胞表达的发育下调蛋白9(NEDD9)是导致肿瘤发生的各种细胞功能的促进因子。本研究的目的是分析黑色素瘤患者血清中NEDD9的水平,以评估其预后、预测和诊断价值。回顾性分析了112例黑色素瘤患者的数据,并采用酶联免疫吸附测定法检测血清NEDD9浓度。患者血清NEDD9水平中位数显著高于对照组。未发现血清NEDD9与任何临床病理参数相关,也未发现其对黑色素瘤生存具有预后价值。因此,血清NEDD9在黑色素瘤中可能具有诊断价值,但其在预后方面的作用仍存在争议。NEDD9在肿瘤血管生成中的重要作用使得有必要努力阐明其与肿瘤微环境的相互作用及其作为恶性肿瘤治疗靶点的潜力。